[NCI CIRB] - S1712 - A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
The purpose of this study is to compare the good and bad effects of adding ruxolitinib to the standard chemotherapy vs. using the standard chemotherapy alone.
This study is also looking at the toxicities, progression free survival and overall survival rates in this patient population.
1- Diagnosis of Chronic Phase CML without any history of progression to accelerated or blast phase CML.
2- Patients must have detectable BCR-ABL transcripts
3- Patients must be receiving treatment with dasatinib or nilotinib as first or second line therapy for a minimum of 6 months prior to registration.
4- Patients must not have received more than 2 TKI.
5- Patients must be expected to remain on the same TKI for the next 12 months
6- ≥ 18 years of age
7 - Labs within range
18 - 100
Healthy Volunteers Needed
Duration of Participation
5 years from the time of registration
Knight Information Line - email@example.com or 503-494-1080